PAVmed Inc. Amends Lucid Diagnostics Stake Filing
Ticker: PAVM · Form: SC 13D/A · Filed: Dec 12, 2024 · CIK: 1624326
Sentiment: neutral
Topics: ownership-change, sec-filing, healthcare
TL;DR
PAVmed Inc. updated its Lucid Diagnostics stake filing (13D/A #4) on 12/12/24.
AI Summary
PAVmed Inc. filed an amendment (No. 4) to its Schedule 13D on December 12, 2024, concerning its beneficial ownership of Lucid Diagnostics Inc. common stock. The filing indicates a change in the reporting person's holdings, though specific new percentages or dollar amounts are not detailed in this excerpt. PAVmed Inc. is the reporting entity, with Lishan Aklog, M.D., identified as Chairman and CEO.
Why It Matters
This filing provides updated information on significant ownership changes in Lucid Diagnostics Inc., which could signal strategic shifts or investor sentiment impacting the company's stock.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can indicate shifts in control or strategy, potentially impacting stock price and requiring investor attention.
Key Players & Entities
- PAVmed Inc. (company) — Reporting entity and former company name holder
- Lucid Diagnostics Inc. (company) — Subject company
- Lishan Aklog, M.D. (person) — Chairman and Chief Executive Officer of PAVmed Inc.
FAQ
What is the specific change in PAVmed Inc.'s beneficial ownership of Lucid Diagnostics Inc. reported in this amendment?
This excerpt does not specify the exact percentage or number of shares changed, only that an amendment (No. 4) was filed on December 12, 2024.
What is the filing date of this Schedule 13D/A amendment?
The filing was made on December 12, 2024.
Who is identified as the Chairman and CEO of PAVmed Inc. in this filing?
Lishan Aklog, M.D. is identified as the Chairman and Chief Executive Officer of PAVmed Inc.
What is the CUSIP number for Lucid Diagnostics Inc. common stock?
The CUSIP number for Lucid Diagnostics Inc. common stock is 54948X 109.
What was PAVmed Inc.'s former company name?
PAVmed Inc.'s former company name was PAXmed Inc., with a date of name change on November 5, 2014.
Filing Stats: 2,174 words · 9 min read · ~7 pages · Grade level 9.4 · Accepted 2024-12-12 16:30:32
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
- $1.25 — of Common Stock at an exercise price of $1.25 per share, with each such stock option
- $148,549 — ions for an aggregate purchase price of $148,549, or approximately $0.874 per share. Mr.
- $0.874 — ase price of $148,549, or approximately $0.874 per share. Mr. Glennon used his persona
- $21.98 million — 2024, the Issuer closed on the sale of $21.98 million in principal amount of Senior Secured C
Filing Documents
- formsc13da.htm (SC 13D/A) — 73KB
- 0001493152-24-049793.txt ( ) — 75KB
Signatures
Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. PAVMED INC. Dated: December 12, 2024 By: /s/ Lishan Aklog Lishan Aklog, M.D. Chief Executive Officer